Year of investment: 2011
Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI). N4I’s products MRWire and MagnaFy are used for navigation to treat cardiovascular diseases and for radiotherapy.
For more information on the company and product(s), please refer to the following video:
Year of investment: 2010
CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company has facilities in Marseille (France) and at the Chemelot Campus.
Year of investment: 2009
FABPulous develops a disposable device which allows for rapid semi-quantitative diagnostic testing in blood or plasma. The first application is for diagnosis of acute myocardial infarction, based on heart-type fatty acid binding protein (H-FABP) as a biomarker. This test is able to demonstrate, within 2-3 minutes after drawing a drop of blood by means of a finger prick, whether or not H-FABP is elevated, which is indicative of an acute myocardial infarction.
Year of investment: 2009
TiGenix is a late-stage regenerative medicine company active in tissue engineering (cartilage repair) and allogeneic cell therapy. It has a marketing agreement with Sobi AB for its ChrondroCelect product in Europe. Its cell therapy products are in advanced stages of clinical trials. TiGenix NV is listed at Euronext Brussels.
Year of investment: 2008
MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customers active in high-throughput screening of biomarkers. In 2014 the shares of Limburg Ventures were sold to the other shareholders.
Year of investment: 2007
PharmaCell is world leader in cell-culturing services using its GMP-certified manufacturing facilities in Maastricht and Geleen. Its customers include the world leaders in commercial cell therapy products. Pharmacell has access to an extensive network which gives it the capability to provide support and/or partnership to R&D companies to bring new products from the lab into the clinic.
Year of investment: 2005
Basic Pharma is an advanced, independent pharmaceutical company primarily engaged in developing, licensing, manufacturing and commercialisation of pharmaceutical and biopharmaceutical products. Basic Pharma delivers a full service package to the Pharmaceutical, Biotech and Medical Device industry.
Year of investment: 2004
In 2009 the company was part of a transaction involving an MBI and which provided a partial exit for shareholders.
The assets were transferred to Fortimedix Holding BV.